Case report
Open access
Sep 2026
HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge
Background Mucinous ovarian carcinoma (MOC) is a rare and relatively chemo resistant subtype of epithelial ovarian cancer for which limited evidence-based guidelines exist. Human Epidermal growth factor Receptor 2 (HER2) overexpression occurs in up to 35% of MOC cases; however, targeted therapies are often used off-lab...
Oriana Krivenko, Nicole Díaz, Jenna Marcus et al.
· Gynecologic Oncology Reports · 0 citations